NYSE ARCA | ETF
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| LLY | Eli Lilly and Company | Healthcare | Drug Manufacturers - General | 10.11% |
| AZN | AstraZeneca PLC | Healthcare | Drug Manufacturers - General | 6.36% |
| 0QIU | Novo Nordisk A/S Class B | 6.2% | ||
| BSX | Boston Scientific Corp | Healthcare | Medical Devices | 6.17% |
| ISRG | Intuitive Surgical Inc | Healthcare | Medical Instruments & Supplies | 4.55% |
| DHR | Danaher Corporation | Healthcare | Diagnostics & Research | 3.68% |
| AMGN | Amgen Inc | Healthcare | Drug Manufacturers - General | 3.58% |
| ZBH | Zimmer Biomet Holdings Inc | Healthcare | Medical Devices | 3.37% |
| COO | The Cooper Companies Inc. | Healthcare | Medical Instruments & Supplies | 3.36% |
| PODD | Insulet Corporation | Healthcare | Medical Devices | 3.07% |
| BMRN | Biomarin Pharmaceutical Inc | Healthcare | Biotechnology | 3.03% |
| BIIB | Biogen Inc | Healthcare | Drug Manufacturers - General | 2.96% |
| CSL | CSL Ltd | Healthcare | Biotechnology | 2.8% |
| NBIX | Neurocrine Biosciences Inc | Healthcare | Drug Manufacturers - Specialty & Generic | 2.7% |
| BMY | Bristol-Myers Squibb Company | Healthcare | Drug Manufacturers - General | 2.53% |
| LONN | Lonza Group AG | Healthcare | Diagnostics & Research | 2.28% |
| 4519 | Chugai Pharmaceutical Co. Ltd. | Healthcare | Drug Manufacturers - General | 2.27% |
| MTD | Mettler-Toledo International Inc | Healthcare | Diagnostics & Research | 2.25% |
| ABBV | AbbVie Inc | Healthcare | Drug Manufacturers - General | 2.07% |
| A | Agilent Technologies Inc | Healthcare | Diagnostics & Research | 2.01% |
The fund invests, under normal circumstances, at least 80% of its net assets plus any borrowings for investment purposes (measured at the time of purchase) in equity investments in U.S. and non-U.S. health care companies. The adviser generally intends to invest in companies that the adviser believes are aligned with key themes associated with innovation in health care, which include, but are not limited to, genomics, precision medicine, technology-enabled procedures, and digital healthcare. The fund is non-diversified.